Opportunity Information: Apply for PAR 15 175
Apply for PAR 15 175
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866 Aging Research.
- This funding opportunity was created on Apr 3, 2015 and posted on Apr 3, 2015.
- Applicants must submit their applications by May 7, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: State governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses City or township governments Public housing authorities/Indian housing authorities Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) Private institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments For profit organizations other than small businesses Public and State controlled institutions of higher education Independent school districts.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity PAR 15-175, titled "Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (R01)," supports research aimed at translating human longevity genetics into practical therapeutic ideas for healthier aging. The central theme is FOXO3, a gene repeatedly associated with exceptional human longevity, and the opportunity is designed to push beyond association studies by focusing on what FOXO3 longevity variants actually do in people and in human-derived biological systems. The emphasis is on studies that can clarify mechanisms and point toward druggable targets or interventions that could help maintain function and reduce age-related decline.
A defining feature of this FOA is its focus on human relevance. It prioritizes in vivo human studies, as well as in vitro work using human cells or tissues, rather than relying mainly on animal models. Projects can examine how naturally occurring FOXO3 variants influence observable traits in humans (phenotypes), how those variants affect cellular behavior and signaling pathways, and how that knowledge can be leveraged to identify and test potential therapeutic targets. The FOA frames potential targets broadly: FOXO3 itself is a candidate, but so are upstream regulators that control FOXO3 activity and downstream effectors that execute FOXO3-driven programs in cells. The overall aim is to connect genotype to mechanism to intervention, with an eye toward healthy aging rather than treatment of a single disease endpoint.
The FOA highlights three main research directions. First, it encourages studies that examine in vivo phenotypic effects of human FOXO3 variants. This can include measuring how longevity-associated variants correlate with human healthspan-related traits, resilience, functional outcomes, or physiological markers, ideally using well-designed human cohorts and robust phenotyping. Second, it supports mechanistic work that elucidates how FOXO3 variants change cellular functions and the pathways that mediate them. In practical terms, that could involve experiments in primary human cells, induced pluripotent stem cell-derived lineages, organoids, or human tissues to determine how variant-specific FOXO3 regulation influences processes tied to aging biology, such as stress responses, metabolism, proteostasis, autophagy, inflammation, DNA repair, or cell survival programs, depending on the hypothesis and model system. Third, it invites research that identifies and evaluates candidate therapeutic targets based on FOXO3-related pathways, including target validation studies and early testing of candidate compounds or other interventions, as long as the rationale is anchored in FOXO3 functional biology and the work remains grounded in human biology.
Administratively, this is an NIH discretionary grant using the R01 mechanism, categorized under health with the CFDA number 93.866 (Aging Research). It does not require cost sharing or matching. The opportunity was posted on April 3, 2015, with an original and final closing date of May 7, 2018, and it was archived on June 7, 2018, meaning it is not currently open for new submissions but remains a useful reference point for the types of FOXO3-focused, human-centered aging research NIH has sought to fund.
Eligibility is broad and includes many types of U.S. and non-U.S. organizations. Eligible applicants include state, county, city/township, and special district governments; public housing authorities; independent school districts; public and private institutions of higher education; nonprofits with and without 501(c)(3) status; small businesses and other for-profit organizations; Native American tribal governments (federally recognized and other than federally recognized) and tribal organizations; and additional categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, AANAPISIs, tribally controlled colleges and universities, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and foreign (non-U.S.) entities. The sponsoring agency is the National Institutes of Health, and the archived announcement is linked at http://grants.nih.gov/grants/guide/pa-files/PAR-15-175.html. For technical issues accessing the announcement, the contact listed is the NIH Office of Extramural Research webmaster (FBOWebmaster@OD.NIH.GOV).
In short, this FOA is essentially a bridge-building program: it pushes investigators to use human studies and human biological systems to explain how FOXO3 longevity variants shape aging-relevant biology, and then to use that mechanistic insight to nominate, validate, and preliminarily test intervention targets within FOXO3-centered regulatory networks, with the long-term goal of informing therapies that support healthy aging.
FAQs: NIH PAR-15-175 (R01) - FOXO3 Human Longevity Variants
What is PAR-15-175?
PAR-15-175 is an NIH grant funding opportunity announcement titled "Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (R01)." It supports research that translates human longevity genetics, specifically FOXO3 longevity-associated variants, into mechanistic understanding and potential therapeutic target ideas aimed at healthier aging.
What is the main scientific focus of this funding opportunity?
The central theme is the FOXO3 gene, which has been repeatedly associated with exceptional human longevity. The opportunity emphasizes moving beyond genetic association by studying what FOXO3 longevity variants actually do in humans and in human-derived biological systems, with the goal of identifying mechanisms and intervention targets relevant to healthy aging.
What is the overall goal of the research supported by this FOA?
The goal is to connect genotype to mechanism to intervention. The FOA encourages research that links naturally occurring FOXO3 variants to measurable human phenotypes and cellular functions, then uses that knowledge to nominate, validate, and preliminarily test potential therapeutic targets within FOXO3-centered pathways to support healthy aging and reduce age-related functional decline.
Does this FOA prioritize human studies over animal models?
Yes. A defining feature is its emphasis on human relevance. It prioritizes in vivo human studies and in vitro work using human cells or tissues rather than projects that rely mainly on animal models.
What types of studies are encouraged under this FOA?
The FOA highlights three main directions: (1) in vivo phenotypic studies of human FOXO3 variants, (2) mechanistic studies clarifying how FOXO3 variants alter cellular functions and signaling pathways in human-derived systems, and (3) research that identifies and evaluates candidate therapeutic targets based on FOXO3-related pathways, including target validation and early testing of candidate compounds or interventions grounded in FOXO3 functional biology.
What are examples of "phenotypic" studies mentioned in the FOA?
Phenotypic studies can include measuring how longevity-associated FOXO3 variants correlate with healthspan-related traits, resilience, functional outcomes, or physiological markers in humans, ideally using well-designed human cohorts and robust phenotyping approaches.
What kinds of human-derived model systems are specifically mentioned?
The FOA mentions mechanistic experiments in primary human cells, induced pluripotent stem cell (iPSC)-derived lineages, organoids, or human tissues to assess how FOXO3 variant-specific regulation affects cellular behavior and pathways relevant to aging biology.
Which biological processes related to aging are within scope for mechanistic studies?
The FOA gives examples of aging-related processes that may be studied depending on the hypothesis and model system, including stress responses, metabolism, proteostasis, autophagy, inflammation, DNA repair, and cell survival programs.
Does the FOA require that FOXO3 itself be the therapeutic target?
No. The FOA frames targets broadly. FOXO3 itself is a candidate, but so are upstream regulators that control FOXO3 activity and downstream effectors that carry out FOXO3-driven cellular programs. The emphasis is on FOXO3-centered regulatory networks that can yield druggable targets or actionable interventions.
Is early-stage testing of interventions allowed under this FOA?
Yes. The FOA invites research that identifies and evaluates candidate therapeutic targets, including target validation studies and early testing of candidate compounds or other interventions, as long as the rationale is anchored in FOXO3 functional biology and the work remains grounded in human biology.
What NIH funding mechanism is used for this opportunity?
This opportunity uses the NIH R01 mechanism, described as an NIH discretionary grant.
What is the CFDA number and program category for this FOA?
The CFDA number is 93.866, and it is categorized under Aging Research.
Is cost sharing or matching required?
No. The opportunity does not require cost sharing or matching.
When was this opportunity posted, and what were the closing dates?
It was posted on April 3, 2015. The original and final closing date was May 7, 2018.
Is PAR-15-175 currently open for new submissions?
No. The announcement was archived on June 7, 2018, which indicates it is not currently open for new submissions. It remains useful as a reference for the kinds of FOXO3-focused, human-centered aging research NIH has sought to fund.
Who is eligible to apply based on the information provided?
Eligibility is broad and includes many U.S. and non-U.S. organizations. Eligible applicants include various levels of government (state, county, city/township, and special district), public housing authorities, independent school districts, public and private institutions of higher education, nonprofits (with and without 501(c)(3) status), small businesses and other for-profit organizations, Native American tribal governments (federally recognized and others) and tribal organizations, and other categories such as HBCUs, Hispanic-serving institutions, Alaska Native and Native Hawaiian-serving institutions, AANAPISIs, tribally controlled colleges and universities, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and foreign (non-U.S.) entities.
Which agency sponsors this FOA?
The sponsoring agency is the National Institutes of Health (NIH).
Where can the archived announcement be found?
The archived NIH announcement is available at http://grants.nih.gov/grants/guide/pa-files/PAR-15-175.html.
Who should be contacted for technical issues accessing the announcement?
For technical issues accessing the announcement, the FOA lists the NIH Office of Extramural Research webmaster at FBOWebmaster@OD.NIH.GOV.
Is the FOA oriented toward treating a single disease or toward healthy aging?
The FOA is oriented toward healthy aging. It emphasizes maintaining function and reducing age-related decline rather than focusing on treatment of a single disease endpoint.
What makes this FOA a "bridge-building" program?
It explicitly pushes investigators to bridge human genetics and practical intervention ideas: using human studies and human biological systems to explain how FOXO3 longevity variants shape aging-relevant biology, then using that mechanistic insight to nominate, validate, and preliminarily test targets within FOXO3-related regulatory networks.
Browse more opportunities from the same category: Health
Next opportunity: FY15 Iraq Mine Risk Education Notice of Funding Opportunity
Previous opportunity: Methods Development in Natural Products Chemistry (R43/R44)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 15 175
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 15 175) also looked into and applied for these:
| Funding Opportunity |
|---|
| National Center for HIV/AIDS, Viral Hepatitis, Sexually Transmitted Diseases and Tuberculosis Prevention (NCHHSTP) Public Health Conference Support Apply for CDC RFA PS15 1507 Funding Number: CDC RFA PS15 1507 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $125,000 |
| Developing professional training programs to increase capacity for effective global health response to humanitarian emergencies Apply for CDC RFA GH15 1624 Funding Number: CDC RFA GH15 1624 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $100,000 |
| Improving Response to and Programming in Humanitarian Emergencies Apply for CDC RFA GH15 1623 Funding Number: CDC RFA GH15 1623 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Understanding and Improving Diagnostic Safety in Ambulatory Care Incidence and Contributing Factors (R01) Apply for PA 15 180 Funding Number: PA 15 180 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $350,000 |
| The NINDS Human Cell and Data Repository (U24) Apply for RFA NS 15 009 Funding Number: RFA NS 15 009 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| The NINDS Human Biomarkers Biospecimen and Data Repository (U24) Apply for RFA NS 15 010 Funding Number: RFA NS 15 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Understanding and Improving Diagnostic Safety in Ambulatory Care Strategies and Interventions (R18) Apply for PA 15 179 Funding Number: PA 15 179 Agency: Agency for Health Care Research and Quality Category: Health Funding Amount: $350,000 |
| Tuberculosis Call to Action (TBC2A) Apply for RFA 386 15 000003 Funding Number: RFA 386 15 000003 Agency: India USAID New Delhi Category: Health Funding Amount: $6,000,000 |
| Rural Opioid Overdose Reversal Grant Program Apply for HRSA 15 146 Funding Number: HRSA 15 146 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Mental Health Research Dissertation Grant to Enhance Workforce Diversity (R36) Apply for PAR 15 181 Funding Number: PAR 15 181 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Indian Health Outreach and Education II MSPI and HIV/AIDS Apply for HHS 2015 IHS NIHOE 2 MSPI 0001 Funding Number: HHS 2015 IHS NIHOE 2 MSPI 0001 Agency: Indian Health Service Category: Health Funding Amount: $150,000 |
| Provide Technical Assistance to GEMA Preparedness Application Ready.Georgia Apply for CDC RFA EH15 1508 Funding Number: CDC RFA EH15 1508 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $145,000 |
| Administrative Supplements for Tobacco Regulatory Research on Tobacco Flavors and Flavorings (Admin Supp) Apply for PA 15 183 Funding Number: PA 15 183 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Statewide Peer Networks for Recovery and Resiliency Apply for SM 15 013 Funding Number: SM 15 013 Agency: Substance Abuse Mental Health Services Adminis. Category: Health Funding Amount: $100,000 |
| Immunization Information Systems (IIS) Sentinel Site Project Apply for CDC RFA IP14 140702CONT15 Funding Number: CDC RFA IP14 140702CONT15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Cooperative Agreement to Support Navigators in Federally facilitated and State Partnership Marketplaces. Apply for CA NAV 15 001 Funding Number: CA NAV 15 001 Agency: CMS Consumer Information Insurance Oversight Category: Health Funding Amount: Case Dependent |
| Community Interoperability and Health Information Exchange Cooperative Agreement Program Apply for II II 15 002 Funding Number: II II 15 002 Agency: Office of the National Coordinator Category: Health Funding Amount: $100,000 |
| PPHF 2015 Nutrition, Physical Activity, and Obesity Programs National Innovative Partnerships for Addressing Obesity through Environmental Supports for Nutrition and Physical Activity financed solely by 2015 Prevention and Public Health Funds Apply for CDC RFA DP13 130403PPHF15 Funding Number: CDC RFA DP13 130403PPHF15 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| NATIONAL ORGANIZATION FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION Apply for CDC RFA DP15 1512 Funding Number: CDC RFA DP15 1512 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,000,000 |
| Centers of Excellence in Ethical, Legal and Social Implications (ELSI) Research (CEER) (RM1) Apply for RFA HG 15 021 Funding Number: RFA HG 15 021 Agency: National Institutes of Health Category: Health Funding Amount: $550,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 15 175", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.